AK104 + paclitaxel + cisplatin + carboplatin

**AK104 + paclitaxel + cisplatin + carboplatin** is a combination regimen under investigation for oncology indications, notably gastric and cervical cancers. AK104 (cadonilimab) is a bispecific monoclonal antibody that simultaneously targets PD-1 (programmed death-1) and CTLA-4 (cytotoxic T-lymphocyte associated protein 4) to inhibit immune checkpoints and enhance antitumor immunity[1][3][7][9]. Paclitaxel is an antimitotic agent that disrupts microtubule function, inhibiting cell division and inducing apoptosis[8], while cisplatin and carboplatin are platinum-based chemotherapeutics causing DNA crosslinking and apoptosis in rapidly dividing cells[2][4][8]. The regimen is being studied especially as first-line or neoadjuvant therapy in gastric/gastroesophageal junction adenocarcinoma and recurrent/metastatic cervical cancer, with preliminary studies demonstrating substantial response rates and manageable toxicity profiles[1][3][7][9].

Brand names

cadonilimab

Other names

AK104 + paclitaxel + cisplatin + carboplatin